" /> Delanzomib - CISMeF





Preferred Label : Delanzomib;

NCIt synonyms : Proteasome Inhibitor CEP 18770; ((1R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido)-3-methylbutyl)boronic Acid;

NCIt definition : An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.;

UNII : 6IF28942WO;

InChIKey : SJFBTAPEPRWNKH-CCKFTAQKSA-N;

CAS number : 847499-27-8;

Molecule name : CEP 18770; CEP-18770; CT-47098; NPH-007098;

Chemical formula : C21H28BN3O5;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
28/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.